Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite the fact that the adjuvant properties of the heat-labile enterotoxins of Escherichia coli(LT) and Vibrio cholerae(CT) have been known for more than 20 years, there are no available oral vaccines containing these molecules as adjuvants, primarily because they are both very potent enterotoxins. A number of attempts with various degrees of success have been made to reduce or eliminate the enterotoxicity of LT and CT so they can safely be used as oral adjuvants or immunogens. In this report we characterize the structural, enzymatic, enterotoxic, and adjuvant properties of a novel mutant of LT, designated LT(R192G/L211A), or dmLT. dmLT was not sensitive to trypsin activation, had reduced enzymatic activity for induction of cyclic AMP in Caco-2 cells, and exhibited no enterotoxicity in the patent mouse assay. Importantly, dmLT retained the ability to function as an oral adjuvant for a coadministered antigen (tetanus toxoid) and to elicit anti-LT antibodies.In vitro and in vivo data suggest that the reduced enterotoxicity of this molecule compared to native LT or the single mutant, LT(R192G), is a consequence of increased sensitivity to proteolysis and rapid intracellular degradation in mammalian cells. In conclusion, dmLT is a safe and powerful detoxified enterotoxin with the potential to function as a mucosal adjuvant for coadministered antigens and to elicit anti-LT antibodies without undesirable side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, a double-mutant labile toxin (dmLT) derived from Escherichia coli is a potent adjuvant that can enhance immune responses to IPV [113,114,115,116].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland
Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., & Steffen, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030595 · Cited by 916 · cited 1×
“Intranasal use of these molecules or their mutants in humans has serious safety risks and has been associated with Bell’s palsy (21, 27).”
BackgroundNew knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
Levine, M. M., Kaper, J. B., Black, R. E., & Clements, M. L. (1983) · Microbiological Reviews · doi:10.1128/mmbr.47.4.510-550.1983 · Cited by 636
Intestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18326 · Cited by 572 · cited 1×
“In intestinal epithelial cells, this induction of cAMP causes a disregulation of cAMP-sensitive ion transport mechanisms, inhibiting intracellular salt absorption, increasing electrolyte transport into the gut lumen, and creating an osmotic gradient favoring intestinal water secretion (12).”
BackgroundProtein Disulfide Isomerase Acts as a Redox-Dependent Chaperone to Unfold Cholera Toxin
Tsai, B., Rodighiero, C., Lencer, W. I., & Rapoport, T. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00289-6 · Cited by 483 · cited 3×
“Tsai et al. demonstrated that protein disulfide isomerase (PDI) in the lumen of the ER functions to disassemble and unfold CT (and presumably LT) once its A-chain has been proteolytically cleaved at Arg192 (38).”
BackgroundInfluentialIntestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318326 · Cited by 468
Dickinson, B. L., & Clements, J. D. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1617-1623.1995 · Cited by 350 · cited 5×
“chromatography in our laboratory as described previously (6, 8, 34).”
BackgroundMethodInfluentialSelf-citationClements, J. D., & Finkelstein, R. A. (1979) · Infection and Immunity · doi:10.1128/iai.24.3.760-769.1979 · Cited by 330 · cited 2×
“chromatography in our laboratory as described previously (6, 8, 34).”
MethodResultSelf-citationMichetti, P., Kreiss, C., Kotloff, K. L., Porta, N., Blanco, J., Bachmann, D., Herranz, M., Saldinger, P. F., Corthésy–Theulaz, I., Losonsky, G., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70063-6 · Cited by 310
Lewis, D. J. M., Huo, Z., Barnett, S., Kromann, I., Giemza, R., Galiza, E., Woodrow, M., Thierry-Carstensen, B., Andersen, P., Novicki, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006999 · Cited by 305 · cited 1×
“Intranasal use of these molecules or their mutants in humans has serious safety risks and has been associated with Bell’s palsy (21, 27).”
BackgroundClements, J. D., Hartzog, N. M., & Lyon, F. L. (1988) · Vaccine · doi:10.1016/0264-410x(88)90223-x · Cited by 284 · cited 1×
“Despite the fact that the adjuvant properties of LT and CT have been known for more than 20 years (7, 11), there are no available oral vaccines containing these molecules as adjuvants, primarily because they are both very potent enterotoxins.”
BackgroundSelf-citation
Research works printed but not linked: 1
- 28. Oplinger, M. L., et al. 1997. Abstr. 37th Intersci. Conf. Antimicrob.
Cited by
Recent Advances in Understanding Enteric Pathogenic Escherichia coli
Croxen, M. A., Law, R. J., Scholz, R., Keeney, K. M., Wlodarska, M., & Finlay, B. B. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-13 · Cited by 1,569
“A recent study characterized a new mutant LT called dmLT that is quickly degraded, has reduced toxicity, and may be useful in oral vaccines (774).”
BackgroundMucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems
Boyaka, P. N. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601775 · Cited by 257
“Approaches used to dissociate the toxicity and the adjuvanticity of the bacterial toxins included partial or complete inactivation of the enzymatic activity of CT (59) and LT (60).”
Status of vaccine research and development for Shigella
Mani, S., Wierzba, T., & Walker, R. I. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.075 · Cited by 229
Pokharel, P., Dhakal, S., & Dozois, C. M. (2023) · Microorganisms · doi:10.3390/microorganisms11020344 · Cited by 207
Buccal and sublingual vaccine delivery
Kraan, H., Vrieling, H., Czerkinsky, C., Jiskoot, W., Kersten, G., & Amorij, J.-P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.060 · Cited by 205
“Building on this mutant, a double mutant of LT, R192G/L211A or dmLT, showed adjuvanticity for a co-administered antigen equivalent to mLT upon oral administration (gastro-intestinal delivery) [66].”
BackgroundNew-age vaccine adjuvants, their development, and future perspective
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1043109 · Cited by 190
“dmLT is a mutated form of its parent molecule LT (124, 125).”
BackgroundThe Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
Clements, J. D., & Norton, E. B. (2018) · mSphere · doi:10.1128/msphere.00215-18 · Cited by 177
“The ribbon diagram of dmLT can be extrapolated from the crystal structure of the partially cleaved LT toxin (1, 2), although there may be as-yet-unresolved changes in three-dimensional (3D) structure due to the amino acid substitutions in the A subunit.”
BackgroundMethodResultSelf-citationVaccine adjuvants: smart components to boost the immune system
Bastola, R., Noh, G., Keum, T., Bashyal, S., Seo, J.-E., Choi, J., Oh, Y., Cho, Y., & Lee, S. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0969-z · Cited by 158
“To reduce the enterotoxicity of native LT, double mutant LT (dmLT) has been developed (Leach et al. 2012) and is a powerful and safe detoxified enterotoxin that can act as mucosal adjuvant for coadministered antigens (Norton et al. 2011).”
BackgroundThe Impact of the Microbiome on Immunity to Vaccination in Humans
de Jong, S. E., Olin, A., & Pulendran, B. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.014 · Cited by 160
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
Toussi, D. N., & Massari, P. (2014) · Vaccines · doi:10.3390/vaccines2020323 · Cited by 181
“molecules, have been tested in experimental vaccine models against bacterial, viral and parasitic infections, in cancer vaccines and in clinical trials [107,115,206,207], but their safety remains under scrutiny [208].”
BackgroundMucosal vaccines and technology
Miquel-Clopés, A., Bentley, E. G., Stewart, J. P., & Carding, S. R. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13285 · Cited by 175
Mucosal vaccine adjuvants update
Rhee, J. H., Lee, S. E., & Kim, S. Y. (2012) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2012.1.1.50 · Cited by 161
Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins
Martinez-Becerra, F. J., Kissmann, J. M., Diaz-McNair, J., Choudhari, S. P., Quick, A. M., Mellado‐Sánchez, G., Clements, J. D., Pasetti, M. F., & Picking, W. L. (2011) · Infection and Immunity · doi:10.1128/iai.06174-11 · Cited by 155
“These mutations effectively reduce enterotoxicity without impacting the adjuvant properties of the molecule (33).”
BackgroundInfluentialSelf-citationDefending the mucosa: adjuvant and carrier formulations for mucosal immunity
Lawson, L. B., Norton, E. B., & Clements, J. D. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.009 · Cited by 140
“One promising candidate for oral, sublingual, rectal, or transcutaneous administration is the newly created double mutant LT(R192G/L211A), which in mouse studies results in equivalent antibody and cellular responses to coadministered antigen as does native LT, but without its associated toxicity [14].”
BackgroundSelf-citationLundgren, A., Bourgeois, L., Carlin, N., Clements, J., Gustafsson, B., Hartford, M., Holmgren, J., Petzold, M., Walker, R., & Svennerholm, A.-M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.10.069 · Cited by 135
Self-citationHolmgren, J. R., Bourgeois, L., Carlin, N., Clements, J. D., Gustafsson, B. I., Lundgren, A., Nygren, E., Tobias, J., Walker, R. I., & Svennerholm, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.03.027 · Cited by 132
Self-citationIntestinal Pathogenic Escherichia coli: Insights for Vaccine Development
Rojas-López, M., Monteiro, R., Pizza, M., Desvaux, M., & Rosini, R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00440 · Cited by 152
“Formalin-or phenol-attenuated bacteria were used in preclinical and clinical phase I studies (Lundgren et al., 2014) and immunized together with an LCTBA hybrid protein (which has seven amino acids in CTB replaced by corresponding amino acids of LTB) and a double mutant LT (dmLT, which has two replacements in the A su…”
Progress and hurdles in the development of vaccines against enterotoxigenicEscherichia coliin humans
Zhang, W., & Sack, D. A. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.37 · Cited by 114
Recent progress toward an enterotoxigenicEscherichia colivaccine
Svennerholm, A., & Lundgren, A. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.12 · Cited by 110
Immune responses and protection in children in developing countries induced by oral vaccines
Qadri, F., Bhuiyan, T. R., Sack, D. A., & Svennerholm, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.012 · Cited by 107
Hall, J. A., Pokrovskii, M., Kroehling, L., Kim, B.-R., Kim, S. Y., Wu, L., Lee, J.-Y., & Littman, D. R. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.013 · Cited by 93
“Oral vaccination— Double mutant E. coli heat labile toxin (R192G/L211A) (dmLT), was produced from E. coli clones expressing recombinant protein as previously described (Norton et al., 2011).”
Norton, E. B., Lawson, L. B., Mahdi, Z., Freytag, L. C., & Clements, J. D. (2012) · Infection and Immunity · doi:10.1128/iai.00181-12 · Cited by 101
“Despite its lack of toxicity, dmLT has adjuvant activity equivalent to that of native LT (37, 48, 55) and was used in the adjuvant studies described below.”
BackgroundMethodResultSelf-citationWalker, R. I. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.11.049 · Cited by 99
Zhang, W., & Sack, D. A. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00224-15 · Cited by 97
“A dmLT (LTR192G/L211A) that was shown to lack toxicity in a patent mouse assay and had greatly reduced activity in stimulating cyclic AMP levels in Caco-2 cells (58) appears to be a safer antigen for inducing anti-LT antibody responses.”
BackgroundLipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection
Corthésy, B., & Bioley, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00431 · Cited by 94
“The most promising derivative is the double mutant LT (R192G/L211A, dmLT) that has no demonstrated side effects in animal application while retaining important adjuvant activity after oral or sublingual administration (121) (122) (123) .”
BackgroundDuan, Q., Xia, P., Nandre, R. M., Zhang, W., & Zhu, G. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00292 · Cited by 93
Hong, S. H., Byun, Y.-H., Nguyen, C. T., Kim, S. Y., Seong, B. L., Park, S., Woo, G.-J., Yoon, Y., Koh, J. T., Fujihashi, K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.10.058 · Cited by 86
Ottsjö, L. S., Flach, C., Clements, J. D., Holmgren, J. R., & Raghavan, S. (2013) · Infection and Immunity · doi:10.1128/iai.01407-12 · Cited by 87
“not only in mice (11) but also in human volunteers given dmLT”
BackgroundMethodSelf-citationHarro, C. D., Bourgeois, A. L., Sack, D. A., Walker, R. I., DeNearing, B., Brubaker, J., Maier, N., Fix, A. D., Dally, L., Chakraborty, S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.025 · Cited by 77
“The adjuvant was produced, purified and characterized [11] at the WRAIR PBF.”
MethodSelf-citationNorton, E. B., Bauer, D. L., Weldon, W. C., Oberste, M. S., Lawson, L. B., & Clements, J. D. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.069 · Cited by 76
Self-citationJones, A., Shen, X., Walter, K. A., LaBranche, C. C., Wyatt, L. S., Tomaras, G. D., Montefiori, D. C., Moss, B., Barouch, D. H., Clements, J. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08739-4 · Cited by 78
Self-citationBhattacharjee, A., Burr, A. B. P., Overacre-Delgoffe, A. E., Tometich, J. T., Yang, D., Huckestein, B. R., Linehan, J. L., Spencer, S. P., Hall, J. A., Harrison, O. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.005 · Cited by 80
Self-citationLarena, M., Holmgren, J. R., Lebens, M., Terrinoni, M., & Lundgren, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401633 · Cited by 83
“Double-mutant LT (dmLT), with more than a 100-fold reduced enterotoxicity compared with native LT, was recently developed (4) and shown to enhance immune responses to various vaccines in animal models (4–8).”
BackgroundMethodInfluentialMucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles
Srivastava, A. K., Gowda, D. V., Madhunapantula, S. V., Shinde, C. G., & Meenakshi, S. S. (2015) · Apmis · doi:10.1111/apm.12351 · Cited by 75
“administered orally together with bicarbonate (31).”
Leach, S., Clements, J. D., Kaim, J., & Lundgren, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051718 · Cited by 71
“The toxins/toxin derivatives used were LT, mLT, dmLT, and LTB (J. Clements, Tulane University, USA [6,18]) as well as CT (Sigma-Aldrich, Germany).”
BackgroundResultSelf-citationAkhtar, M., Chowdhury, M. I., Bhuiyan, T. R., Kaim, J., Ahmed, T., Rafique, T. A., Khan, A., Rahman, S. I. A., Khanam, F., Begum, Y. A., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.11.040 · Cited by 76
“To further enhance the immunogenicity of the vaccine, particularly when given at low dosages, the vaccine may be combined with the double mutant LT (dmLT) adjuvant [14,17].”
BackgroundMethodKauffman, R. C., Bhuiyan, T. R., Nakajima, R., Mayo-Smith, L. M., Rashu, R., Hoq, M. R., Chowdhury, F., Khan, A. I., Rahman, A., Bhaumik, S. K., et al. (2016) · mBio · doi:10.1128/mbio.02021-16 · Cited by 67
“CT, LT, and EltB were provided by Clemens and prepared as previously described (42).”
Novel antigens for enterotoxigenicEscherichia colivaccines
Fleckenstein, J. M., Sheikh, A., & Qadri, F. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.905745 · Cited by 77
“L211A) that prevent proteolytic activation of LT into its catalytically active form [91].”
BackgroundKaminski, R. W., Wu, M., Turbyfill, K. R., Clarkson, K. A., Tai, B., Bourgeois, A. L., Verg, L. L. V. D., Walker, R. I., & Oaks, E. V. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00683-13 · Cited by 71
“nized with the same doses of Sfl2aWC mixed with 5 g dmLT (20).”
MethodNovotny, L. A., Jurcisek, J. A., Ward, M. O., Jordan, Z. B., Goodman, S. D., & Bakaletz, L. O. (2015) · Molecular Microbiology · doi:10.1111/mmi.12934 · Cited by 68
“The amino acid substitutions render dmLT nontoxic while maintaining adjuvant properties (Norton et al., 2011).”
BackgroundEl-Kamary, S. S., Cohen, M. B., Bourgeois, A. L., Van De Verg, L., Bauers, N., Reymann, M., Pasetti, M. F., & Chen, W. H. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00464-13 · Cited by 62
“LTR192G/L211A, or dmLT, is a genetically modified derivative of wild-type ETEC heat-labile enterotoxin created by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine (23).”
BackgroundOral cholera vaccines and their impact on the global burden of disease
Wierzba, T. F. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1504155 · Cited by 63
Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses
Clements, J. D., & Freytag, L. C. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00214-16 · Cited by 59
“The combined R192G/L211A mutations in dmLT prevent proteolytic activation of the molecule, reduce enzymatic activity by 1,000fold, completely eliminate enterotoxicity, and preserve the full adjuvant properties of native LT (18).”
BackgroundSelf-citationRuan, X., Robertson, D. C., Nataro, J. P., Clements, J. D., & Zhang, W. (2014) · Infection and Immunity · doi:10.1128/iai.01394-13 · Cited by 57
“In contrast to the 1A:5B holotoxin-structured dmLT (LTR192G/L211A) (25), this monomeric dmLT molecule is a single peptide that consisted of only one copy of the A subunit and one copy of the B subunit.”
BackgroundSelf-citationADP-ribosylating enterotoxins as vaccine adjuvants
Lycke, N. Y., & Lebrero‐Fernández, C. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.015 · Cited by 57
Lundgren, A., Leach, S., Tobias, J., Carlin, N., Gustafsson, B., Jertborn, M., Bourgeois, L., Walker, R. I., Holmgren, J. R., & Svennerholm, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.063 · Cited by 54
Frederick, D. R., Goggins, J. A., Sabbagh, L. M., Freytag, L. C., Clements, J. D., & McLachlan, J. B. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.70 · Cited by 55
“dmLT was obtained as previously described.(50) Briefly, purified dmLT was prepared from E.”
Self-citationCárdeno, A., Magnusson, M. K., Quiding-Järbrink, M., & Lundgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-20740-3 · Cited by 53
White, J. A., Blum, J. S., Hosken, N. A., Marshak, J. O., Duncan, L., Zhu, C., Norton, E. B., Clements, J. D., Koelle, D. M., Chen, D., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.32253 · Cited by 51
“One polypeptide chain of dmLT has been altered to eliminate the enterotoxicity typical for this family of bacterial binary toxins; it is considered safe and has entered human clinical trials.(26,29) It is an advanced clinical candidate both as an antigen to protect against bacterial diarrhea and as an adjuvant.”
BackgroundSelf-citationVaccination of carp against SVCV with an oral DNA vaccine or an insect cells-based subunit vaccine
Embregts, C. W. E., Rigaudeau, D., Tacchi, L., Pijlman, G. P., Kampers, L. F. C., Veselý, T., Pokorová, D., Boudinot, P., Wiegertjes, G. F., & Forlenza, M. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.03.028 · Cited by 50
Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection
Forsyth, V. S., Himpsl, S. D., Smith, S. N., Sarkissian, C. A., Mike, L. A., Stocki, J. A., Sintsova, A., Alteri, C. J., & Mobley, H. L. T. (2020) · mBio · doi:10.1128/mbio.00555-20 · Cited by 47
Side-by-Side Comparison of Gene-Based Smallpox Vaccine with MVA in Nonhuman Primates
Golden, J. W., Josleyn, M. D., Mucker, E. M., Hung, C., Loudon, P. T., Wu, T. ‐., & Hooper, J. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042353 · Cited by 46
“, protein) due to toxicity [54,55,56], Arrington, J.”
Novotny, L. A., Clements, J. D., & Bakaletz, L. O. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.10.033 · Cited by 46
“It is proposed that dmLT promotes activation of various cell types, including DCs, with a resultant mixed Th1/Th2-type immune response [19].”
BackgroundInfluentialSelf-citationNovotny, L. A., & Bakaletz, L. O. (2016) · Cellular Microbiology · doi:10.1111/cmi.12575 · Cited by 53
Holmgren, J. R., Nordqvist, S. L., Blomquist, M., Jeverstam, F., Lebens, M., & Raghavan, S. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.073 · Cited by 49
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines
Ou, B., Yang, Y., Lv, H., Lin, X., & Zhang, M. (2023) · BioDrugs · doi:10.1007/s40259-022-00575-1 · Cited by 47
“, Streptococcus pneumoniae [23], Helicobacter pylori [24, 25], tetanus toxoid [17], CT [18], and ETEC [26].”
BackgroundRecent progress towards development of aShigellavaccine
Camacho, A. I., Irache, J. M., & Gamazo, C. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.135 · Cited by 51
Read, L. T., Hahn, R. W., Thompson, C. C., Bauer, D. L., Norton, E. B., & Clements, J. D. (2014) · Infection and Immunity · doi:10.1128/iai.02496-14 · Cited by 54
“toxin (CT) were purified as described previously (10, 11, 24).”
MethodSelf-citationLeach, S., Lundgren, A., Carlin, N., Löfstrand, M., & Svennerholm, A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.06.006 · Cited by 45
Pig vaccination strategies based on enterotoxigenic Escherichia coli toxins
Dubreuil, J. D. (2021) · Brazilian Journal of Microbiology · doi:10.1007/s42770-021-00567-3 · Cited by 43
Lebens, M., Terrinoni, M., Karlsson, S. L., Larena, M., Gustafsson‐Hedberg, T., Källgård, S., Nygren, E., & Holmgren, J. R. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.002 · Cited by 43
Recent advances in nontoxicEscherichia coliheat-labile toxin and its derivative adjuvants
Ma, Y. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1182868 · Cited by 43
“1% of the enzymatic activity of LT and induced no detectible fluid accumulation when given to mice by the intragastric route, while retaining immunogenicity and adjuvanticity without undesirable side effects [43,46].”
BackgroundMethodLundgren, A., Jertborn, M., & Svennerholm, A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.055 · Cited by 42
Synthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside
Ding, S., Alexander, E., Liang, H., Kulchar, R. J., SINGH, R. K., Herzog, R. W., Daniell, H., & Leong, K. W. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00482 · Cited by 51
Leung, D. T., Rahman, M. A., Mohasin, M., Riyadh, M. A., Patel, S. M., Alam, M. M., Chowdhury, F., Khan, A. I., Kalivoda, E. J., Aktar, A., et al. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05124-11 · Cited by 41
“Experimental studies in animal models evaluating oral adjuvanticity of the toxin have demonstrated that CT stimulates a greater mucosal immune response than CtxB alone (4, 6); unfortunately, the use of CT as a vaccine component is limited due to its toxicity, although mutant toxoids are being explored for their use in…”
BackgroundArifuzzaman, M., Rashu, R., Leung, D. T., Hosen, M., Bhuiyan, T. R., Bhuiyan, M. S., Rahman, M. A., Khanam, F., Saha, A., Charles, R. C., et al. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00196-12 · Cited by 41
“cholerae O1-specific antigens, including cholera toxin (CT) (Sigma), cholera holotoxin containing the G33D variant homopentameric B subunit (mCT) (48), the G33D variant homopentameric B subunit (mCTB), and an immuno-cross-reactive double mutant R192G/L211A variant of heatlabile enterotoxin (dmLT) of Escherichia coli (…”
BackgroundSelf-citationBernstein, D. I., Pasetti, M. F., Brady, R. C., Buskirk, A. D., Wahid, R., Dickey, M., Cohen, M. B., Baughman, H., El-Khorazaty, J. A., Maier, N., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.12.011 · Cited by 41
“Therefore, double mutants were developed and evaluated here [4, 9].”
BackgroundAlam, M. M., Bufano, M. K., Xu, P., Kalsy, A., Yu, Y., Freeman, Y. W., Sultana, T., Rashu, M. R., Desai, I., Eckhoff, G., et al. (2014) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002683 · Cited by 37
“These molecules have in common their retained immunoadjuvanticity but markedly diminished enterotoxicity [18].”
BackgroundMethodSelf-citationMucosal Vaccine Approaches for Prevention of HIV and SIV Transmission
Kozlowski, P. A., & Aldovini, A. (2018) · Current Immunology Reviews · doi:10.2174/1573395514666180605092054 · Cited by 40
“[216] Norton EB, Lawson LB, Freytag LC, Clements JD.”
Valli, E., Harriett, A. J., Nowakowska, M. K., Baudier, R. L., Provosty, W. B., McSween, Z., Lawson, L. B., Nakanishi, Y., & Norton, E. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-51356-w · Cited by 39
Self-citationNorton, E. B., Branco, L. M., & Clements, J. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136302 · Cited by 39
“1 μg trypsin-activated LT before the levels of intracellular cAMP were assessed using a cAMP assay kit (R&D Systems) [17, 18].”
BackgroundMethodSelf-citationVaccines Against Escherichia coli
Nesta, B., & Pizza, M. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_111 · Cited by 43
Collins, N., & Belkaid, Y. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028860 · Cited by 38
“A possible link between the microbiota and vaccine efficacy was first shown in a model of oral vaccination using heat-labile enterotoxin of enterotoxigenic Escherichia coli as adjuvant (LT R192G/L211A) (Hall et al. 2008; Norton et al. 2011).”
BackgroundThe study ofH. pyloriputative candidate factors for single- and multi-component vaccine development
Mirzaei, N., Poursina, F., Moghim, S., Rashidi, N., & Safaei, H. G. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2017.1291578 · Cited by 35
Ghose, C., Verhagen, J., Chen, X., Yu, J., Huang, Y., Chenesseau, O., Kelly, C. P., & Ho, D. D. (2013) · Infection and Immunity · doi:10.1128/iai.01074-12 · Cited by 38
“Additional experiments with a double mutant such as LT(r192g/l211a) may provide a safer alternative with an even greater reduction in enterotoxicity (38).”
BackgroundThe Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
Chakraborty, S., Randall, A. Z., Vickers, T. J., Molina, D., Harro, C. D., DeNearing, B., Brubaker, J., Sack, D. A., Bourgeois, A. L., Felgner, P. L., et al. (2019) · npj Vaccines · doi:10.1038/s41541-019-0131-7 · Cited by 35
Rational application of nanoadjuvant for mucosal vaccine delivery system
Dewangan, H. K. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112791 · Cited by 37
Mucosal vaccine development for respiratory viral infections
Lin, Y., Hu, Z., Fu, Y., & Peng, H. (2023) · hLife · doi:10.1016/j.hlife.2023.12.005 · Cited by 35
“One example is the double-mutant LT (dmLT), created by detoxifying LT [107].”
Luo, Q., Vickers, T. J., & Fleckenstein, J. M. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00248-16 · Cited by 36
Evolution of Adjuvants Across the Centuries
Garçon, N., & Friede, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00006-7 · Cited by 38
Ottsjö, L. S., Jeverstam, F., Yrlid, L., Wenzel, A. U., Walduck, A. K., & Raghavan, S. (2016) · Immunology · doi:10.1111/imm.12676 · Cited by 30
“and activation of DCs might be related to the low amounts of cAMP induced as reported by Norton et al in Caco-2 cell lines [18].”
Huang, J., Duan, Q., & Zhang, W. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.00849-18 · Cited by 29
Hongli, L., Xukui, L., Lei, T., Li, W., Si, L., & Jin, Z. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22292 · Cited by 28
Maciel, M., Bauer, D. L., Baudier, R. L., Bitoun, J. P., Clements, J. D., Poole, S., Smith, M. A., Kaminski, R. W., Savarino, S. J., & Norton, E. B. (2019) · Infection and Immunity · doi:10.1128/iai.00460-19 · Cited by 28
“induces measurable fluid secretion in the intestines (31, 54).”
BackgroundMethodResultSelf-citationNovotny, L. A., Clements, J. D., Goodman, S. D., & Bakaletz, L. O. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00563-16 · Cited by 28
“or dmLT, a double mutant of Escherichia coli heat-labile enterotoxin (21), to potentiate the immune response induced by the incorporated antigens, and efficacy was assessed in a polymicrobial model that more closely mimics the natural progression of disease in children in whom an upper respiratory tract viral infectio…”
BackgroundSelf-citationAkhtar, M., Nizam, N. N., Basher, S. R., Hossain, L., Akter, S., Bhuiyan, T. R., Qadri, F., & Lundgren, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654872 · Cited by 27
“Oral administration of up to 250 μg of dmLT did not cause any enterotoxicity in a mouse assay, while ≥5 μg of native LT caused substantial intestinal fluid secretion (8).”
BackgroundMesenchymal stem cells as a novel vaccine platform
Tomchuck, S. L., Norton, E. B., Garry, R. F., Bunnell, B. A., Morris, C. A., Freytag, L. C., & Clements, J. D. (2012) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2012.00140 · Cited by 30
“An ELISA for serum anti-gp120 IgG antibodies graphed as 405 nm absorbance versus sera dilution was preformed as previously described (Norton et al., 2011).”
MethodSelf-citationHelicobacter pylori vaccination: Is there a path to protection?
Anderl, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.11939 · Cited by 27
Ibañez, A. E., Coria, L. M., Carabajal, M. V., Delpino, M. V., Risso, G. S., Cobiello, P. L. G., Rinaldi, J., Barrionuevo, P., Bruno, L. A., Frank, F. M., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.011 · Cited by 26
Shigella Outer Membrane Protein PSSP-1 Is Broadly Protective against Shigella Infection
Kim, J., Rho, S., Kim, S. H., Kim, H. J., Song, H. J., Kim, E. J., Kim, R. Y., Kim, E. H., Sinha, A., Dey, A., et al. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00661-14 · Cited by 26
“In this study, PSSP-1, when added to cholera toxin (CT) (10) or the double mutant (R192G/L211A) of heat-labile toxin (dmLT) of Escherichia coli (11), showed cross-protection against multiple Shigella species and serotypes when tested in a mouse pneumonia model.”
BackgroundBiofilm Biology and Vaccine Strategies for Otitis Media Due to Nontypeable Haemophilus influenzae
Novotny, L. A., Brockman, K. L., Mokrzan, E. M., Jurcisek, J. A., & Bakaletz, L. O. (2018) · Journal of Pediatric Infectious Diseases · doi:10.1055/s-0038-1660818 · Cited by 27
Zhong, Y., Chen, J., Liu, Y., Zhang, Y., Tang, C., Wang, X., Wang, P., Chen, W., Wei, B., & Liu, M. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104229 · Cited by 26
Opinion: Making Inactivated and Subunit-Based Vaccines Work
Chua, B. Y. L., Sekiya, T., & Jackson, D. C. (2018) · Viral Immunology · doi:10.1089/vim.2017.0146 · Cited by 24
“Saponins (32) and bacterial exotoxins, including heat-labile toxins, (84) have also been studied as potential adjuvants.”
Adjuvant‐mediated enhancement of the immune response to HIV vaccines
Ratnapriya, S., Perez‐Greene, E., Schifanella, L., & Herschhorn, A. (2021) · FEBS Journal · doi:10.1111/febs.15814 · Cited by 24
Walker, R. I., & Clifford, A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.11.048 · Cited by 22
Lee, S., Picking, W. L., & Tzipori, S. R. (2014) · Microbes and Infection · doi:10.1016/j.micinf.2014.07.013 · Cited by 22
“Because ETEC LT can be removed by neutralizing antibodies [22,23], the SL & ID route would provide better clearance of the toxin.”
BackgroundInfluentialRole of nutrition, infection, and the microbiota in the efficacy of oral vaccines
Bhattacharjee, A., & Hand, T. W. (2018) · Clinical Science · doi:10.1042/cs20171106 · Cited by 22
Tarique, A. A., Kalsy, A., Arifuzzaman, M., Rollins, S. M., Charles, R. C., Leung, D. T., Harris, J. B., LaRocque, R. C., Sheikh, A., Bhuiyan, M. S., et al. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05689-11 · Cited by 21
“Immune responses against CT and LT are cross-reactive (21), and nontoxic derivatives of LT have been developed that maintain immunoadjuvanticity (14, 25, 28, 29, 33).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Norton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D.
- Affiliations
- Tulane University (US)
- Corresponding author
- Clements, John D.
- Venue
- Clinical and Vaccine Immunology
- Publisher
- American Society for Microbiology
- Published
- 2011-02-02
- Volume
- 18
- Issue
- 4
- Pages
- 546-551
- ISSN
- 1556-679X (ISSN-L)
- 1556-6811
- PMC
- PMC3122563
- OpenAlex
- W2133080338
- Cited by
- 221
- References
- 40
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 2 · 2023: 25 · 2022: 8 · 2021: 10 · 2020: 13 · 2019: 14 · 2018: 20 · 2017: 17 · 2016: 20 · 2015: 17 · 2014: 18 · 2013: 17 · 2012: 16
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Clinical and Vaccine Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Louisiana Board of Regents
- National Institutes of Health
- National Institute of Biomedical Imaging and Bioengineering (EB006493-04, R01EB006493)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- heat-labile enterotoxin, Escherichia coli, oral adjuvant, trypsin activation, enterotoxicity, tetanus toxoid, mucosal immunization, intracellular degradation, proteolysis
- MeSH terms
- Adjuvants, Immunologic, Administration, Oral, Animals, Antibodies, Bacterial, Antitoxins, Bacterial Toxins, Enterotoxins, Female, Humans, Mice, Inbred BALB C, Tetanus Toxoid, Caco-2 Cells, Amino Acid Substitution, Escherichia coli Proteins, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.